We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Mannose Treatment Enhances Chemotherapy and Slows Growth of Cancers

By LabMedica International staff writers
Posted on 05 Dec 2018
Cancer researchers have found that treatment with mannose leads to growth retardation in several tumor types in vitro and in a mouse model system and enhances cell death in response to major forms of chemotherapy.

Mannose is a simple sugar found in fruits. More...
It is not broken down in the bloodstream and is concentrated in the bladder where it prevents bacterial adherence to the bladder wall. When taken as a supplement, mannose binds to bacterial receptors, blocking the ability of bacteria to adhere to the epithelial cell wall. Animal studies have reported the efficacy of mannose in decreasing bacteriuria within one day. The safety of mannose has been confirmed in long-term studies in mice, and it has been used in humans for the treatment of a rare carbohydrate deficient glycoprotein syndrome.

Investigators at Cancer Research UK (London, United Kingdom) have been interested in how tumor cells respond to different forms of sugar. To this end, they treated various types of cancer cells growing in culture with mannose and examined how mice with pancreatic, lung, or skin cancer responded when mannose was added to their drinking water and given as an oral treatment.

Results published in the November 21, 2018, online edition of the journal Nature revealed that mannose caused growth retardation in several types of tumor in vitro and enhanced cell death in response to major forms of chemotherapy. These effects also occurred in vivo in mice following the oral administration of mannose, without significantly affecting the weight and health of the animals.

Mechanistically, mannose was taken up by the same transporter(s) as glucose but accumulated as mannose-6-phosphate in cells, and this impaired the further metabolism of glucose in glycolysis, the tricarboxylic acid cycle, the pentose phosphate pathway, and glycan synthesis.

Susceptibility to mannose was shown to be dependent on the levels of the enzyme phosphomannose isomerase (PMI). Cells with low levels of PMI were sensitive to mannose, whereas cells with high levels were resistant, but could be made sensitive by RNA-interference-mediated depletion of the enzyme. Data from tissue microarray studies showed that PMI levels also varied greatly between different patients and different tumor types, indicating that PMI levels could be used as a biomarker to direct the successful administration of mannose.

Senior author Dr. Kevin Ryan, professor of molecular cell biology at the University of Glasgow Beatson Institute (United Kingdom), said, "Tumors need a lot of glucose to grow, so limiting the amount they can use should slow cancer progression. The problem is that normal tissues need glucose as well, so we cannot completely remove it from the body. In our study, we found a dosage of mannose that could block enough glucose to slow tumor growth in mice, but not so much that normal tissues were affected. This is early research, but it is hoped that finding this perfect balance means that, in the future, mannose could be given to cancer patients to enhance chemotherapy without damaging their overall health. Our next step is investigating why treatment only works in some cells, so that we can work out which patients might benefit the most from this approach. We hope to start clinical trials with mannose in people as soon as possible to determine its true potential as a new cancer therapy."

Related Links:
Cancer Research UK
University of Glasgow Beatson Institute


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Serological Pipet Controller
PIPETBOY GENIUS
New
Whole Blood Control
Lyphochek Whole Blood Control
New
Myocardial Infarction Test
Finecare cTn I/NT-proBNP Rapid Quantitative Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Gut microbes may help in recognizing and treating pancreatic cancer (Photo courtesy of Adobe Stock)

Gut Microbes Could Enable Early Detection and Treatment of Pancreatic Cancer

Pancreatic cancer remains one of the most serious and challenging diseases in oncology due to its difficulty in detection and limited treatment options. Now, a new international collaborative study suggests... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Microbiology

view channel
Image: The U.S. FDA-cleared IntelliSep rapid host response diagnostic represents a breakthrough in sepsis care (Photo courtesy of Cytovale)

Rapid Diagnostic Test Slashes Sepsis Mortality by 39%

Sepsis remains one of the most challenging and fatal conditions in contemporary healthcare, accounting for nearly one-third of all hospital-related deaths in the United States. In emergency departments... Read more

Industry

view channel
Image: The knowledge transfer partnership will further develop technology to rapidly diagnose serious and high-risk infectious diseases (Photo courtesy of Aston University)

Aston University and BG Research Partner to Commercialize Groundbreaking Medical Diagnostic

Technology that can rapidly diagnose high-consequence infectious diseases will take a major step forward towards commercialization, thanks to a new partnership. A Knowledge Transfer Partnership (KTP)... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.